Search - tctmd.com

Displaying 21 - 40 of 254

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for September 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2023

October 03, 2023

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

September 18, 2023

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

August 31, 2023

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

July 11, 2023

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

News Daily News

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

June 05, 2023

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

News Daily News

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

January 19, 2023

Top Coronary Artery Disease News of 2022

News Daily News

Top Coronary Artery Disease News of 2022

Yael L. Maxwell

December 29, 2022

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

December 16, 2022

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

News Daily News

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

December 01, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

Apixaban Again Linked to Less Bleeding in AF Patients

News Daily News

Apixaban Again Linked to Less Bleeding in AF Patients

Michael O'Riordan

October 31, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

June 29, 2022

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

Fewer Diabetic Complications Seen When NOACs Given for AF

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

February 22, 2022

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

January 20, 2022

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

News Daily News

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

January 11, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.